Matching slides 303,780
Current window 200,971-201,000
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all

Component

200,971-201,000 of 303,780

filter-aware
40
The slide presents a WACC calculation with low, base, and high scenarios, showing inputs like Market Risk Premium, Beta, and Risk-Free Rate.Morgan Stanley | Investment Banking Pitch Book | 41 slides · Morgan Stanley
Consulting deck Investment bank Beat · Solution & Approach1 hit
41
Morgan Stanley | Investment Banking Pitch Book | 41 slidesMorgan Stanley | Investment Banking Pitch Book | 41 slides · Morgan Stanley
Consulting deck Investment bank Beat · Solution & Approach1 hit
02
Myovant Sciences | Results Presentation Deck | 34 slidesMyovant Sciences | Results Presentation Deck | 34 slides · Myovant Sciences
Conference presentation Investor relations 1 hit
03
Myovant Sciences | Results Presentation Deck | 34 slidesMyovant Sciences | Results Presentation Deck | 34 slides · Myovant Sciences
Conference presentation Investor relations 1 hit
04
Myovant Sciences | Results Presentation Deck | 34 slidesMyovant Sciences | Results Presentation Deck | 34 slides · Myovant Sciences
Conference presentation Investor relations 1 hit
05
The slide emphasizes the 'first and only' status of the drug for these two conditions.Myovant Sciences | Results Presentation Deck | 34 slides · Myovant Sciences
Conference presentation Investor relations 1 hit
06
Uses a bar chart visualization to represent patient population segments.Myovant Sciences | Results Presentation Deck | 34 slides · Myovant Sciences
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
07
The slide uses icons to represent four distinct pillars of growth: product profile, market synergy, financial milestone, and strategic pipeline expansion.Myovant Sciences | Results Presentation Deck | 34 slides · Myovant Sciences
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
08
Myovant Sciences | Results Presentation Deck | 34 slidesMyovant Sciences | Results Presentation Deck | 34 slides · Myovant Sciences
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
09
Includes citations for data points.Myovant Sciences | Results Presentation Deck | 34 slides · Myovant Sciences
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
10
Includes a disclaimer about the 24-month usage limit due to bone loss risk.Myovant Sciences | Results Presentation Deck | 34 slides · Myovant Sciences
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
11
The slide uses a timeline-based process diagram to illustrate the clinical trial structure.Myovant Sciences | Results Presentation Deck | 34 slides · Myovant Sciences
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
12
Clinical trial data presentation with p-values and sample sizes.Myovant Sciences | Results Presentation Deck | 34 slides · Myovant Sciences
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
13
The slide includes a footnote defining the response rate criteria and a disclaimer that it is not for promotion.Myovant Sciences | Results Presentation Deck | 34 slides · Myovant Sciences
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
14
The chart highlights a 74.1% mean reduction in NRS score for MYFEMBREE vs 26.4% for placebo at week 24.Myovant Sciences | Results Presentation Deck | 34 slides · Myovant Sciences
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
15
The slide highlights a 49.7% reduction in NMPP NRS score at week 24 for the pooled MYFEMBREE group compared to 36.0% for placebo.Myovant Sciences | Results Presentation Deck | 34 slides · Myovant Sciences
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
16
The chart highlights a 57.9% mean reduction in pain domain score for the pooled MYFEMBREE group versus 32.6% for placebo at week 24.Myovant Sciences | Results Presentation Deck | 34 slides · Myovant Sciences
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
17
The chart shows a greater reduction in pain scores for the treatment group compared to placebo, with p < 0.05 significance indicated for both trials.Myovant Sciences | Results Presentation Deck | 34 slides · Myovant Sciences
Conference presentation Investor relations Loop · Before After1 hit
18
Includes clinical trial data for opioid rescue usage at baseline vs month 6.Myovant Sciences | Results Presentation Deck | 34 slides · Myovant Sciences
Conference presentation Investor relations 1 hit
20
Clinical safety data table for MYFEMBREE.Myovant Sciences | Results Presentation Deck | 34 slides · Myovant Sciences
Conference presentation Investor relations 1 hit
21
Data from SPIRIT 1 and 2 studies only.Myovant Sciences | Results Presentation Deck | 34 slides · Myovant Sciences
Conference presentation Investor relations 1 hit
22
The chart shows a decrease in BMD for the treatment group compared to a slight increase for the placebo group.Myovant Sciences | Results Presentation Deck | 34 slides · Myovant Sciences
Conference presentation Investor relations 1 hit
23
The slide compares a control/observational group against a treatment group (SPIRIT study) to show BMD changes.Myovant Sciences | Results Presentation Deck | 34 slides · Myovant Sciences
Conference presentation Investor relations 1 hit
24
The table presents efficacy percentages for MYFEMBREE vs placebo (in parentheses) for three pain metrics, plus safety data.Myovant Sciences | Results Presentation Deck | 34 slides · Myovant Sciences
Conference presentation Investor relations Beat · Solution1 hit
25
Myovant Sciences | Results Presentation Deck | 34 slidesMyovant Sciences | Results Presentation Deck | 34 slides · Myovant Sciences
Conference presentation Investor relations 1 hit
26
The slide uses a Venn diagram to illustrate the intersection of Efficacy, Safety & Tolerability, and Clear, Simple Dosing.Myovant Sciences | Results Presentation Deck | 34 slides · Myovant Sciences
Conference presentation Investor relations 1 hit
27
Myovant Sciences | Results Presentation Deck | 34 slidesMyovant Sciences | Results Presentation Deck | 34 slides · Myovant Sciences
Conference presentation Investor relations 1 hit
28
Uses a Venn diagram to illustrate target overlap.Myovant Sciences | Results Presentation Deck | 34 slides · Myovant Sciences
Conference presentation Investor relations 1 hit
29
The slide uses a donut chart to visualize the split between initial coverage and ongoing payer discussions.Myovant Sciences | Results Presentation Deck | 34 slides · Myovant Sciences
Conference presentation Investor relations Beat · Market Size1 hit
30
The slide uses a hub-and-spoke diagram centered on a patient photo to illustrate support services.Myovant Sciences | Results Presentation Deck | 34 slides · Myovant Sciences
Conference presentation Investor relations 1 hit